SEC Company Response from Clinuvel Pharmaceuticals (CUVL) — Jul 15, 2026
Clinuvel Pharmaceuticals Ltd
Date: July 15, 2026 · CIK: 0001290877 · Accession: 0001493152-26-033274
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-43353
Letter
Clinuvel Pharmaceuticals Limited
July 15, 2026
Via EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, D.C., 20549
Attention: Vanessa Robertson
Bonnie Baynes Joe McCann Lauren Sprague Hamill
Re: Clinuvel Pharmaceuticals Limited
Registration Statement on Form 20-F
File No. 001-43353
Ladies and Gentlemen:
Pursuant to Rule 12d1-2 promulgated under the Securities Exchange Act of 1934, as amended, Clinuvel Pharmaceuticals Limited (the "Registrant") hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to cause the Registration Statement on Form 20-F (File No. 001-43353) to become effective at 4:00 p.m. Eastern time on July 17, 2024, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request by telephone call to the staff of the Commission.
Very truly yours,
Clinuvel Pharmaceuticals Limited
Show Raw Text
CORRESP 1 filename1.htm Clinuvel Pharmaceuticals Limited July 15, 2026 Via EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C., 20549 Attention: Vanessa Robertson Bonnie Baynes Joe McCann Lauren Sprague Hamill Re: Clinuvel Pharmaceuticals Limited Registration Statement on Form 20-F File No. 001-43353 Ladies and Gentlemen: Pursuant to Rule 12d1-2 promulgated under the Securities Exchange Act of 1934, as amended, Clinuvel Pharmaceuticals Limited (the "Registrant") hereby requests that the U.S. Securities and Exchange Commission (the "Commission") take appropriate action to cause the Registration Statement on Form 20-F (File No. 001-43353) to become effective at 4:00 p.m. Eastern time on July 17, 2024, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request by telephone call to the staff of the Commission. Very truly yours, Clinuvel Pharmaceuticals Limited By: /s/ Philippe Wolgen Name: Philippe Wolgen Title: Managing Director and Chief Executive Officer